RT Journal Article
SR Electronic
T1 Impact of Proactive Integrated Care on Chronic Obstructive Pulmonary Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20107110
DO 10.1101/2020.05.19.20107110
A1 Koff, Patricia B.
A1 Min, Sung-joon
A1 Diaz, Debora L. P.
A1 Freitag, Tammie J.
A1 James, Shannon S.
A1 Voelkel, Norbert F.
A1 Linderman, Derek J.
A1 del Valle, Fernando Diaz
A1 Albert, Richard K.
A1 Bull, Todd M.
A1 Beck, Arne
A1 Stelzner, Thomas J.
A1 Ritzwoller, Debra P.
A1 Kveton, Christine M.
A1 Carwin, Stephanie
A1 Ghosh, Moumita
A1 Keith, Robert L.
A1 Westfall, John M.
A1 Vandivier, R. William
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.19.20107110.abstract
AB Background. Up to 50% of COPD patients do not receive recommended care for COPD. To address this important issue, we developed Proactive Integrated Care (Proactive iCare), a healthcare delivery model that couples integrated care with remote monitoring. Methods. We conducted a prospective, quasi-randomized clinical trial in 511 patients with advanced COPD, or a recent COPD exacerbation, to test whether Proactive iCare impacts patient-centered outcomes and healthcare utilization. Patients were allocated to Proactive iCare (n = 352) or Usual Care (n = 159), and were examined for changes in quality of life using the St. George’s Respiratory Questionnaire (SGRQ), symptoms, guideline-based care, and healthcare utilization. Findings. Proactive iCare improved the total SGRQ by 7 – 9 units (p < 0.0001), symptom SGRQ by 9 units (p < 0.0001), activity SGRQ by 6 – 7 units (p < 0.001) and impact SGRQ by 7 – 11 units (p < 0.0001) at 3, 6 and 9 months, compared with Usual Care. Proactive iCare increased the 6-minute walk distance by 40 m (p < 0.001), reduced COPD-related urgent office visits by 76 visits per 100 subjects (p < 0.0001), identified unreported exacerbations, and decreased smoking (p = 0.01). Proactive iCare also improved cough, sputum, shortness of breath, the BODE index and oxygen titration (p < 0.05). Mortality in the Proactive iCare group (1.1%) was not significantly different than mortality in the Usual Care group (3.8%; p = 0.08). Interpretation. Results suggest that linking integrated care with remote monitoring improves the lives of people with advanced COPD.Competing Interest StatementGrant funding for research but no other competing interests: RWV, PBK, SJM, DLPD, TJF, SSJ, NFW, DJL, AB, TJS, DPR, CMK, SC, RLK and JMW received funding from the Colorado Cancer, Cardiovascular Disease and Chronic Pulmonary Disease Prevention, Early Detection and Treatment Program (CCPD). RWV and MG received funding from the National Institutes of Health. Mixed competing interests: PBK worked for Robert Bosch Healthcare from 2010 to 2015 and for Philips Healthcare from 2015 to 2017, after the study was completed. No Competing Interests: RKA and TMB head no conflicts of interest. Clinical TrialNCT01044927 The clinical trial was posted with clincaltrials.gov on January 8 2010, but the study started on September 2006. The study was posted retrospectively because the authors did not understand that it should have been posted before the first patient was enrolled. Funding StatementThis study was funded by the Colorado Cancer, Cardiovascular Disease and Chronic Pulmonary Disease Prevention, Early Detection and Treatment Program and the National Institutes of Health (HL129938-03). Other funding of authors for the work: RWV, PBK, SJM, DLPD, TJF, SSJ, NFW, DJL, AB, TJS, DPR, CMK, SC, RLK and JMW received funding from the Colorado Cancer, Cardiovascular Disease and Chronic Pulmonary Disease Prevention, Early Detection and Treatment Program (CCPD). RWV and MG received funding from the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript is provided in the manuscript and in the attached supplemental data.